Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting

Core Insights - Liquidia Corporation will present two oral presentations at the CHEST 2025 annual meeting focusing on new data from the ASCENT trial related to LIQ861 DPI treprostinil in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1][2] Group 1: Presentation Details - The first presentation titled "Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from ASCENT" will be held on October 21, 2025, at 10:20 a.m. CT, presented by Dr. Dan Lachant [3] - The second presentation titled "Safety and Exploratory Efficacy Data of LIQ861 DPI Treprostinil in PH-ILD: ASCENT to Week 16" will also take place on October 21, 2025, at 1:52 p.m. CT, presented by Dr. Nicholas Kolaitis [3] Group 2: ASCENT Study Overview - The ASCENT study is an open-label, prospective, multicenter trial evaluating the safety and tolerability of LIQ861 in subjects with WHO Group 1 and 3 pulmonary hypertension, specifically focusing on a cohort of 54 subjects with PH-ILD [4] - The primary objective of the study is to assess the safety and tolerability of LIQ861, while exploratory objectives include evaluating its effects on exercise capacity, functional class, biomarkers, and imaging assessments [4] Group 3: Product Information - YUTREPIA™ is an inhaled dry-powder formulation of treprostinil designed for the treatment of pulmonary arterial hypertension (PAH) and PH-ILD, aimed at improving exercise ability [5] - The product utilizes Liquidia's PRINT technology, which allows for the creation of drug particles that are precise and uniform, enhancing deposition in the lungs [5] Group 4: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a current emphasis on pulmonary hypertension and applications of its proprietary PRINT technology [6] - The company has developed YUTREPIA™ as its first approved product and is also working on L606, an investigational sustained-release formulation of treprostinil [6]